Pneumoconiosis medical therapy

Jump to navigation Jump to search

Pneumoconiosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pneumoconiosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pneumoconiosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pneumoconiosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pneumoconiosis medical therapy

CDC on Pneumoconiosis medical therapy

Pneumoconiosis medical therapy in the news

Blogs on Pneumoconiosis medical therapy

Directions to Hospitals Treating Pneumoconiosis

Risk calculators and risk factors for Pneumoconiosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD

Overview

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR   The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Medical Therapy

  • There is no effective drug treatment for most pneumoconiosis. Cases that have progressed can be administered oxygen and severe cases would benefit from lung transplants. Asbestosis is also associated with lung cancer with an increased risk if the patient smokes and therefore patients are advised to quit smoking. [1] It is important to advise the patient's occupation of their exposure and prevent it further with the availability of personal protective equipment. [2]

References

  1. Cookson W, De Klerk N, Musk AW, Glancy JJ, Armstrong B, Hobbs M (1986). "The natural history of asbestosis in former crocidolite workers of Wittenoom Gorge". Am Rev Respir Dis. 133 (6): 994–8. doi:10.1164/arrd.1986.133.6.994. PMID 3013058.
  2. Pelucchi C, Pira E, Piolatto G, Coggiola M, Carta P, La Vecchia C (2006). "Occupational silica exposure and lung cancer risk: a review of epidemiological studies 1996-2005". Ann Oncol. 17 (7): 1039–50. doi:10.1093/annonc/mdj125. PMID 16403810.

Template:WH Template:WS